Innova Biosciences Appoints Steve Howell as Non-Executive Director
News Feb 03, 2016
Innova Biosciences (Innova) has announced the appointment of Professor Steve Howell to the Board of Directors.
Steve has over 20 years of experience building and growing life science enterprises, including founding life science investment company Innova Partnerships in 2006. Prior to this he was Director of Business Development at Alere Inc, and Research Director at Unipath Ltd, after joining Unilever Plc.
He is visiting Professor of Commercial Innovation at Kings College London and also advises the Scottish and Irish governments on high growth businesses and life science strategy.
Tim Bernard, Chairman of the Board at Innova Biosciences, commented: “We are delighted to welcome Steve to the Board of Directors. His knowledge and experience will be a valuable addition to the company as we continue to expand.”
Professor Howell said: “Innova Biosciences’ world leading bioconjugation technology business is backed by a team of dedicated executives, scientists and customer service personnel. I am very pleased to be joining the Board, to help lead Innova through its next stages of development.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE